Publications by authors named "Joel Vacus"

Claim this Profile
A
An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis.
Sébastien Pomel, Sandrine Cojean, Valérie Pons, Jean-Christophe Cintrat, Laetitia Nguyen, Joël Vacus

J Antimicrob Chemother· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales.
Neetu Gupta, Romain Noël, Amélie Goudet, Karen Hinsinger, Aurélien Michau, Joël Vacus

Chem Biol Interact· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route.
Kaluvu Balaraman, Nashira Campos Vieira, Fathi Moussa, Joël Vacus, Sandrine Cojean

Biomed Pharmacother· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials.
Nashira Campos Vieira, Christine Herrenknecht, Joel Vacus, Alain Fournet, Christian Bories

Biomed Pharmacother· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis